Todd W. Kelley

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi et al. · Cancer Cell · 2014 · 363 citations · Full text

Hematological Malignancy, Ph Chromosome-positive Leukemia, Genetics +7

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage et al. · Cancer Cell · 2019 · 239 citations · Full text

Allosteric Inhibitor Asciminib, Medicine, Immunology +8

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Jamshid S. Khorashad, Todd W. Kelley, Philippe Szankasi et al. · Blood · 2012 · 218 citations · Full text

Macrophage Colony-stimulating Factor Promotes Cell Survival through Akt/Protein Kinase B

Todd W. Kelley, Mandy M. Graham, Andrea I. Doseff et al. · Journal of Biological Chemistry · 1999 · 170 citations · Full text

Age-related mutations and chronic myelomonocytic leukemia

Clinton C. Mason, Jamshid S. Khorashad, Srinivas K. Tantravahi et al. · Leukemia · 2015 · 138 citations · Full text

Hematological Malignancy, Chromatin, Medicine +6